Aptose begins APTO-253 clinical study in individuals with relapsed or refractory hematologic malignancies Aptose Biosciences Inc. , a clinical-stage company developing brand-new therapeutics and molecular diagnostics that focus on the underlying mechanisms of cancers, today announced dosing of the initial patient in its Stage 1b clinical research of APTO-253 in individuals with relapsed or refractory hematologic malignancies. Epigenetic suppression of the KLF4 gene has been reported as an integral transforming event in severe myeloid leukemia and high-risk myelodysplastic syndromes, and Aptose is certainly a pioneer in advancing KLF4 induction as a new therapeutic approach for the treating these patient populations, commented William G.If a mother has plentiful resources after that it could make sense to invest in creating a son because he is likely to produce even more grandchildren than would a daughter. However, in leaner moments having a girl is a safer wager. Although sex is determined by fathers, mothers therefore appear able to favour the advancement of one sex of infant instead of another. The mechanism is not yet understood in mammals, but it is well known from IVF analysis that high levels of glucose encourage the growth and advancement of male embryos while inhibiting female embryos. In humans, skipping breakfast depresses glucose levels and so could be interpreted by the body as indicating poor environmental conditions and low meals availability. The group of women getting involved in the analysis was representative of the UK average in terms of the weight, health and lifestyle.